Human Metabolome Technologies, Inc. (6090.T)
- Previous Close
696.00 - Open
696.00 - Bid 694.00 x --
- Ask 700.00 x --
- Day's Range
694.00 - 699.00 - 52 Week Range
501.00 - 723.00 - Volume
2,200 - Avg. Volume
8,993 - Market Cap (intraday)
4.073B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
15.48 - EPS (TTM)
44.89 - Earnings Date May 14, 2025
- Forward Dividend & Yield 30.00 (4.31%)
- Ex-Dividend Date Jun 27, 2025
- 1y Target Est
--
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
www.humanmetabolome.comRecent News: 6090.T
View MorePerformance Overview: 6090.T
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6090.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6090.T
View MoreValuation Measures
Market Cap
4.08B
Enterprise Value
2.70B
Trailing P/E
15.51
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.95
Price/Book (mrq)
2.12
Enterprise Value/Revenue
1.93
Enterprise Value/EBITDA
6.97
Financial Highlights
Profitability and Income Statement
Profit Margin
18.97%
Return on Assets (ttm)
6.83%
Return on Equity (ttm)
14.35%
Revenue (ttm)
1.4B
Net Income Avi to Common (ttm)
265M
Diluted EPS (ttm)
44.89
Balance Sheet and Cash Flow
Total Cash (mrq)
1.6B
Total Debt/Equity (mrq)
11.32%
Levered Free Cash Flow (ttm)
263.5M